期刊
LEUKEMIA & LYMPHOMA
卷 52, 期 3, 页码 394-399出版社
INFORMA HEALTHCARE
DOI: 10.3109/10428194.2010.546015
关键词
-
资金
- Canadian Cancer Society
- Ortho Biotech
Bortezomib and gemcitabine have each shown activity as single agents in mantle cell lymphoma (MCL), which is incurable. The purpose of this phase II study was to determine the efficacy and safety of the previously unstudied combination of bortezomib and gemcitabine in patients with relapsed or refractory MCL. Patients were eligible if they had relapsed MCL with 1--3 prior therapies. Patients were treated with gemcitabine 1000 mg/m
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据